SCHEMBL18708446

SCHEMBL18708446

C=C1c2ccccc2C(=O)N1c1ccccc1-c1nnc(-c2ccc(C(=O)O)cc2)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.56
▸ RAB9A P51151 5/20 0.56
▸ ALDH1A1 P00352 2/20 0.47
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ SCN2A Q99250 1/20 0.46
▸ KMT2A Q03164 1/20 0.44
▸ MYC P01106 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ABCG2 Q9UNQ0 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ NR1H4 Q96RI1 2/20 0.40
▸ APEX1 P27695 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796836 0.92 NPC1 (0.62) NPC1RAB9AALDH1A1CA12CA1
SCHEMBL18708460 0.88 ALDH1A1 (0.50) NPC1RAB9AALDH1A1KMT2AMYC
SCHEMBL12171938 0.82 CA12 (0.70) NPC1RAB9ACA12CA1CA2
SCHEMBL12171792 0.81 NPC1 (0.64) NPC1RAB9AALDH1A1KMT2AMYC
SCHEMBL12871392 0.79 ALDH1A1 (0.58) NPC1RAB9AALDH1A1KMT2AMYC
SCHEMBL19153437 0.79 NPC1 (0.54) NPC1RAB9AALDH1A1CA12CA1
SCHEMBL5203777 0.75 NPC1 (0.72) NPC1RAB9AALDH1A1KMT2AMYC
SCHEMBL12171480 0.75 RAB9A (0.81) NPC1RAB9AALDH1A1KMT2AMYC
SCHEMBL4883318 0.74 NPC1 (1.00) NPC1RAB9AALDH1A1CA1CA2
SCHEMBL14403356 0.74 RAB9A (0.46) NPC1RAB9AALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9611230-B2 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease PTC THERAPEUTICS, INC. (US) 2017-04-04 — — US disclosed
Send feedback